Nurix Therapeutics (NRIX) Cash & Equivalents (2019 - 2026)

Nurix Therapeutics (NRIX) has reported Cash & Equivalents for 8 consecutive years, with $67.7 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Cash & Equivalents fell 19.67% year-over-year to $67.7 million; the TTM figure through May 2026 stood at $67.7 million (down 19.67% YoY), while the FY2025 annual figure was $247.0 million, up 124.52% from the prior year.
• Cash & Equivalents eased to $67.7 million in Q2 2026 per NRIX's latest filing, from $71.2 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $247.0 million in Q4 2025 and bottomed at $33.6 million in Q1 2023.
• Historically, Cash & Equivalents has averaged $79.0 million across 5 years, with a median of $69.4 million in 2026.
• Annual changes were most pronounced in 2022 — Cash & Equivalents tumbled 77.93% — and 2024, when it soared 134.12%.
• Nurix Therapeutics' Cash & Equivalents stood at $64.5 million in 2022, then dropped by 15.27% to $54.6 million in 2023, then jumped by 101.36% to $110.0 million in 2024, then surged by 124.52% to $247.0 million in 2025, then slumped by 72.59% to $67.7 million in 2026.
• Business Quant data shows NRIX's Cash & Equivalents at $67.7 million in Q2 2026, $71.2 million in Q1 2026, and $247.0 million in Q4 2025.